Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 12, 2013, Pages 2269-2276

  Evans, D Gareth R ^a,b   Ingham, Sarah L ^b,c   Buchan, Iain ^c   Woodward, Emma R ^d   Byers, Helen ^a   Howell, Anthony ^b   Maher, Eamonn R ^d   Newman, William G ^a   Lalloo, Fiona ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; DNA SCREENING; FEMALE; FIRST DEGREE RELATIVE; GENE MUTATION; GENOTYPE; GROUPS BY AGE; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84890109193     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0316-T     Document Type: Article

References (30)

1. Evans G, Bahar N, Easton D, Halpin J, Hopwood P, McIntosh A, et al. (2004 updated 2006) clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer, London: National Collaborating Centre for Primary Care/University of Sheffield. NICE guideline CG041. www.nice.org.uk
2. Evans DGR, Baildam AD, Anderson E, Brian A, Shenton A, Vasen HF, et al. Risk reducing mastectomy: outcomes in 10 European Centres. J Med Genet 2009;46:254-8.
3. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evand DG, et al. MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78.
4. Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smoth L, et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet. 2007;44:10-15.
5. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting. BMC Cancer 2008;8:155.
6. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. A genome-wide association study identifies multiple novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
7. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010;42:504-7.
8. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, et al.on behalf of CIMBA. Common breast cancerpredisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008;82:937-48.
9. Antoniou A, Beesly J, McGuffog L, Sinilnikova OM, Healey S, Nauhausen SL, et al.on behalf of CIMBA. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2-mutation carriers: implications for risk prediction. Cancer Res 2010;70:9742-54.
10. Gronwald J, Cybulski C, Lubinski J, Narod SA. Phenocopies in breast cancer 1 (BRCA1) families: Implications for genetic counselling. J Med Genet 2007;44:e76.
11. Rowan E, Poll A, Narod SA. A prospective study of breast cancer risk in relatives of BRCA1/BRCA2 mutation carriers. J Med Genet 2007;44: e89.
12. Korde LA, Mueller CM, Loud JT, Struewing JP, Nichols K, Greene MH, et al. No evidence of excess breast cancer risk among mutationnegativewomen from BRCAmutation-positive families. Breast Cancer Res Treat 2011;125:169-73.
13. Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, et al. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat 2010; 119:409-14.
14. Kurian AW, Gong GD, John EM, Johnston DA, Felberg A, West DW, et al. Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the breast cancer family registry. J Clin Oncol 2011;29:4505-9.
15. Harvey SL, Milne RL, McLachlan SA, Friedlander ML, Birch KE, Weideman P, et al. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families. Breast Cancer Res Treat 2011;130:1057-61.
16. Clayton D, Hills M. Statistical models in epidemiology. Oxford: Oxford University Press; 1993, p148.
17. Evans DGR, Eccles DM, Rahman N, Young K, Bulman M, Amir E, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation, outperforms existing models including BRCAPRO. J Med Genet 2004;41:474-80.
18. Latif A, Hadfield KD, Roberts SA, Shenton A, Lalloo F, Black GC, et al. Breast cancer susceptibility variants alter risks in familial disease. J Med Gen 2010;47:126-31.
19. Evans DGR, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, et al. Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: a new paradigm for cancer prevention. Cancer Prev Res 2012;5:943-51.
20. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62: 676-89.
21. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336: 1401-8.
22. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewishwomen with breast cancer. J Natl Cancer Inst 1999;91:1241-7.
23. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-7.
24. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-6.
25. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
26. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002;94: 1221-6.
27. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, et al. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 2012; 14:R33.
28. Vos JR, de Bock GH, Teixeira N, van der Kolk DM, Jansen L, Mourits MJ, et al. Proven non-carriers in BRCA families have an earlier age of onset of breast cancer. Eur J Cancer 2013;pii:S0959-8049(13)00148-2.
29. Evans DG, Howell A. Breast cancer risk for noncarriers of familyspecific BRCA1 and BRCA2 mutations: more trouble with phenocopies. J Clin Oncol 2012;30:1142-3.
30. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23: 11-30.